Extracellular vesicles released from mesenchymal stromal cells stimulate bone growth in osteogenesis imperfecta

• Published in: Cytotherapy (Oxford, England) England), 2018-01, Vol.20 (1), p.62-73
• Main Authors: Otsuru, Satoru, Desbourdes, Laura, Guess, Adam J., Hofmann, Ted J., Relation, Theresa, Kaito, Takashi, Dominici, Massimo, Iwamoto, Masahiro, Horwitz, Edwin M.
• Format: Article
• Language: English
• Subjects: Animals; Bone Development; Cell Proliferation; cellular therapy; Child; chondrocytes; Chondrocytes - cytology; Disease Models, Animal; Endopeptidase K - metabolism; extracellular vesicles; Extracellular Vesicles - metabolism; growth; Humans; Mesenchymal Stem Cells - metabolism; mesenchymal stromal cells; Mice, Inbred C57BL; MicroRNAs - metabolism; osteogenesis imperfecta; Osteogenesis Imperfecta - pathology; Ribonucleases - metabolism; Solubility
• ISSN: 1465-3249; 1477-2566
• DOI: 10.1016/j.jcyt.2017.09.012

Systemic infusion of mesenchymal stromal cells (MSCs) has been shown to induce acute acceleration of growth velocity in children with osteogenesis imperfecta (OI) despite minimal engraftment of infused MSCs in bones. Using an animal model of OI we have previously shown that MSC infusion stimulates chondrocyte proliferation in the growth plate and that this enhanced proliferation is also observed with infusion of MSC conditioned medium in lieu of MSCs, suggesting that bone growth is due to trophic effects of MSCs. Here we sought to identify the trophic factor secreted by MSCs that mediates this therapeutic activity. To examine whether extracellular vesicles (EVs) released from MSCs have therapeutic activity, EVs were isolated from MSC conditioned medium by ultracentrifugation. To further characterize the trophic factor, RNA or microRNA (miRNA) within EVs was depleted by either ribonuclease (RNase) treatment or suppressing miRNA biogenesis in MSCs. The functional activity of these modified EVs was evaluated using an in vitro chondrocyte proliferation assay. Finally, bone growth was evaluated in an animal model of OI treated with EVs. We found that infusion of MSC-derived EVs stimulated chondrocyte proliferation in the growth plate, resulting in improved bone growth in a mouse model of OI. However, infusion of neither RNase-treated EVs nor miRNA-depleted EVs enhanced chondrocyte proliferation. MSCs exert therapeutic effects in OI by secreting EVs containing miRNA, and EV therapy has the potential to become a novel cell-free therapy for OI that will overcome some of the current limitations in MSC therapy.